Market Intelligence, Clinical Progress, and High-Purity Reagents for Ubiquitin-Specific Protease 21 Inhibitor and DUBTAC Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for USP21 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | USP21 Recombinant Protein (Active & Catalytic Inactive C221A Mutant) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic assays and DUBTAC binding studies. |
View USP21 Products |
| Gene Delivery | USP21 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to evaluate substrate stabilization. |
View USP21 Products |
| Benchmark Ab | Anti-USP21 Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and intracellular target engagement. |
View USP21 Products |
| Validator | USP21 siRNA Set For knockdown verification and phenotypic phenocopying of small molecule inhibitors. |
View USP21 Products |
| Related Target A | USP7 Critical for selectivity counter-screening. High sequence homology in the catalytic domain requires precise off-target profiling. |
View USP7 Products |
| Related Target B | OTUB1 Deubiquitinating enzyme involved in similar immune evasion pathways; essential for specificity profiling panels. |
View OTUB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DUB Family Selectivity Profiling | Panel of related USP enzymes (USP7, USP14, USP2) available with verified purity (>95%) and sequence integrity. |
| DUBTAC Mechanism Validation | Catalytically inactive USP21 (C221A) mutant protein available to differentiate binding from enzymatic activity. |
| Lack of Controls | Sequence-verified clinical-grade benchmark recombinant antibodies included. |
| False Positives in Small Molecule HTS | Validated siRNA sets included for target-specific knockdown to confirm on-target cellular effects. |
Live USP21 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for USP21 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein stabilizers (DUBTACs) and oncology indications. As first-generation deubiquitinating enzyme (DUB) inhibitors reach the clinic, the next wave of R&D is targeting USP21's role in immune evasion and therapeutic resistance in solid tumors.
USP21 acts as a critical regulator of protein stability by removing ubiquitin chains from key oncogenic substrates (such as GLI1, GATA3, and STING). Consequently, modulating USP21 offers a dual therapeutic angle: direct inhibition to destabilize oncogenes in cancer, or recruitment via DUBTACs to rescue degraded tumor suppressors or essential proteins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Mission Therapeutics, Ubiquigent | Solid Tumors (NSCLC, Pancreatic), Immunotherapy resistance | High-throughput screening (HTS) using active USP21 recombinant protein and selectivity panels. |
| DUBTACs (Stabilizers) | Vicinitas Therapeutics, Arvinas | Hepatocellular Carcinoma, Inflammatory Diseases | Ternary complex formation assays requiring high-purity wild-type and C221A mutant USP21. |
| RNA Interference | Alnylam, Academic Consortia | Oncology, Fibrotic Diseases | Lentiviral-mediated stable cell line construction for in vivo validation. |